España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
MEI Pharma
MEIP
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$2.50
0.05
2.01%
At close: -
$2.70
0.20
8.00%
After Hours: Dec 12, 8:05 AM EDT
Get Report
Comment
MEI Pharma (MEIP) Forecast
News
Earnings
MEI Pharma (MEIP) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for MEI Pharma (NASDAQ:MEIP) Stock
MEI Pharma Stock (NASDAQ: MEIP)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 22, 2024
Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining
Anthony Noto
Sunday, November 17, 2024
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
Anthony Noto
Tuesday, November 12, 2024
MEI Pharma Q1 EPS $(1.20) Down From $8.46 YoY
Benzinga Newsdesk
Friday, October 25, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
Thursday, September 19, 2024
MEI Pharma Says As Of June 30, 2024, Have $38...
Benzinga Newsdesk
Tuesday, July 23, 2024
Laidlaw & Co. Downgrades MEI Pharma to Hold
Benzinga Newsdesk
Monday, July 22, 2024
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
MEI Pharma shares are trading higher after th...
Benzinga Newsdesk
MEI Pharma To Consider Strategic Alternatives...
Benzinga Newsdesk
Thursday, May 16, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Thursday, May 09, 2024
MEI Pharma Q3 2024 Adj EPS $(1.37) Beats $(1....
Benzinga Newsdesk
Friday, April 12, 2024
Stifel Maintains Hold on MEI Pharma, Maintain...
Benzinga Newsdesk
Thursday, April 11, 2024
MEI Pharma Aligns On Strategy To Advance Voru...
Benzinga Newsdesk
MEI Pharma Reports Initial Data From Clinical...
Benzinga Newsdesk
Tuesday, March 26, 2024
MEI Pharma Announces Enrollment Initiated In ...
Benzinga Newsdesk
Monday, February 19, 2024
5 Value Stocks In The Healthcare Sector
Benzinga Insights
Tuesday, February 13, 2024
MEI Pharma Q2 2024 GAAP EPS $(1.66) Misses $(...
Benzinga Newsdesk
Thursday, January 18, 2024
MEI Pharma Filed U.S. Patent Application #20240016781: Treatment Of KRAS Mutant Cancers
Charles Gross
Monday, January 08, 2024
A Look Into Healthcare Sector Value Stocks
Benzinga Insights
Monday, December 11, 2023
MEI Pharma Reports Clinical Data On Oral CDK9...
Benzinga Newsdesk
Thursday, November 16, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Thursday, November 09, 2023
CORRECTION: MEI Pharma Q1 EPS $8.46 Beats $(2...
Benzinga Newsdesk
MEI Pharma Q1 EPS $8.46 Beats $(2.12) Estimat...
Benzinga Newsdesk
Monday, November 06, 2023
MEI Pharma Declares Special Cash Dividend Of ...
Benzinga Newsdesk
Wednesday, November 01, 2023
MEI Pharma Enters Agreement With Anson Funds ...
Benzinga Newsdesk
Tuesday, October 17, 2023
MEI Pharma Files Definitive Consent Revocatio...
Benzinga Newsdesk
Friday, October 13, 2023
Chief Medical Officer at MEI Pharma Acquires Company Stock Options Worth 30,000 Shares
Benzinga Insights
Monday, October 02, 2023
MEI Pharma Says Board Approved Adoption Of Li...
Benzinga Newsdesk
Wednesday, September 27, 2023
Stifel Maintains Hold on MEI Pharma, Lowers P...
Benzinga Newsdesk
Tuesday, September 26, 2023
MEI Pharma Q4 Adj EPS $(1.51), Sales $1.46M B...
Benzinga Newsdesk
MEI Pharma Stockholders Anson And Cable Car F...
Benzinga Newsdesk
10% Owner of MEI Pharma Purchased $219K In Stock
Benzinga Insights
329K Reasons To Be Bullish On MEI Pharma Stock
Benzinga Insights
Earnings Scheduled For September 26, 2023
Benzinga Insights
Monday, September 25, 2023
Earnings Outlook For MEI Pharma
Benzinga Insights
Monday, September 18, 2023
MEI Pharma Confirms Receipt Of Director Nomin...
Benzinga Newsdesk
Wednesday, August 16, 2023
MEI Pharma Announces First Patient Dosed In Clinical Study Evaluating ME-344 Plus Bevacizumab In Patients With Previously Treated Metastatic Colorectal Cancer
Happy Mohamed
Tuesday, August 15, 2023
MEI Pharma Granted U.S. Patent #11723893: Isoflavonoid compositions and methods for the treatment of cancer
Charles Gross
Thursday, July 27, 2023
Mei Pharma Said On July 26, Board Named Justin J. File As CFO And Corporate Secretary, Effective As Of August 1, 2023
Charles Gross
Monday, July 24, 2023
Sunday, MEI Pharma Did Not Obtain Necessary S...
Benzinga Newsdesk
Monday, July 17, 2023
MEI Pharma Encourages Shareholders To Vote FOR The Infinity Transaction
Happy Mohamed
Monday, July 10, 2023
Infinity Pharmaceuticals Says Second Proxy Advisory Firm Recommends Shareholders To Approve Proposed Merger
Vandana Singh
Tuesday, June 27, 2023
MEI Pharma Encouragea Shareholders Not To Be ...
Benzinga Newsdesk
Anson Funds, Cable Car Capital Issue Statemen...
Benzinga Newsdesk
Tuesday, June 13, 2023
MEI Pharma Announces Planned Departure Of Chi...
Benzinga Newsdesk
Wednesday, June 07, 2023
MEI Pharma President and CEO Awarded $1.23M Worth of Stock Options
Benzinga Insights
Friday, June 02, 2023
CORRECTION: Ticker For MEI Pharma Is MEIP
Benzinga Newsdesk
Thursday, June 01, 2023
Anson Funds Says "We Believe The Board's Outright Rejection Of Our Acquisition Proposal, Without Any Effort To Engage With Us, Represents A Complete Derogation Of Its Fiduciary Duties To The Company's Stockholders..."
Happy Mohamed
Anson Funds And Cable Car Capital, Which Collectively Own 14.8% Of MEI Pharma, Inc., Have Issued A Statement In Response To The Rejection Of Their Acquisition Proposal To Acquire All Outstanding Shares Of MEIP For $8/Share
Happy Mohamed
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch